tinlarebant

News

The first therapy for sight-robbing Stargardt disease could be on the way, as Belite Bio's tinlarebant hits the mark in a phase 3 trial.

News

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.